NHS organisations should take into account the reasons why the manufacturer did not make an evidence submission when considering whether or not to recommend local use of cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti‑platelet therapy. If, after doing this, organisations still wish to consider cangrelor for reducing atherothrombotic events in people undergoing percutaneous coronary intervention or awaiting surgery requiring interruption of anti‑platelet therapy, they should follow the advice set out in NHS Commissioning Board and Clinical Commissioning Groups (Responsibilities and Standing Rules) Regulations 2012, which outlines the approach that should be adopted in circumstances in which NICE guidance is unavailable. NICE will review the position at any point if the manufacturer indicates that it wishes to make a full submission.
© National Institute for Health and Care Excellence 2015. All rights reserved. NICE copyright material can be downloaded for private research and study, and may be reproduced for educational and not‑for‑profit purposes. No reproduction by or for commercial organisations, or for commercial purposes, is allowed without the written permission of NICE.